REAL SCIENCE. REAL POSSIBILITIES.A naturally occurring form of NAD involved in cellular energy, NADH draws interest around fatigue, energy and broader metabolic health.
NADH is most often discussed around energy and fatigue because it plays a direct part in the process cells use to produce energy. Human supplement research exists, but it is much smaller than the wider NAD+ field.
These cards show what NADH is best known for and where the interest comes from. When you want the detail, open Research for the studies or Evidence for a quick view of how strong the support is.
The main reasons this compound attracts attention. The Research and Evidence sections give you the deeper scientific picture.
NADH helps carry energy through the chain of reactions that ultimately allows cells to produce usable energy.
That biological role is well established, although taking NADH does not automatically mean someone will feel more energetic or perform better.
Fatigue is one of the main reasons NADH has been studied as a supplement and remains a common reason for interest today.
Small human trials and reviews have produced mixed results, so there is not yet strong evidence for a broad anti-fatigue effect.
NADH has also been explored in some neurological conditions, which has led to wider interest around the brain and cognition.
The evidence is limited to particular settings and does not establish NADH as a general cognitive enhancer.
NADH works as part of a closely balanced system with NAD+, helping cells move energy and manage chemical reactions efficiently.
This is important underlying biology, but the effect of taking NADH depends on how it is absorbed, distributed and used by different tissues.
NADH is most often discussed around energy and fatigue because it plays a direct part in the process cells use to produce energy. Human supplement research exists, but it is much smaller than the wider NAD+ field.
That biological role is well established, although taking NADH does not automatically mean someone will feel more energetic or perform better.
Small human trials and reviews have produced mixed results, so there is not yet strong evidence for a broad anti-fatigue effect.
The evidence is limited to particular settings and does not establish NADH as a general cognitive enhancer.
This is important underlying biology, but the effect of taking NADH depends on how it is absorbed, distributed and used by different tissues.
86 people with chronic fatigue syndrome; 77 completed the study
73 people with chronic fatigue syndrome
This score reflects completed human outcome evidence. A registered or recruiting trial does not count until results are reported.
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Research themes are shown separately from the strength of the human evidence so biological interest is not confused with proven clinical benefit.
Recurring themes from peptide and wellness communities, shown alongside what published research currently suggests.
NADH is mainly explored for fatigue and mental or physical energy. The biological role is clear, while supplement trials are small, mixed and sometimes combine NADH with another ingredient.
Experiences can reveal recurring goals, perceived changes and practical questions that formal studies may not yet address. They can suggest what deserves investigation, but cannot isolate the effect of one compound from rehabilitation, time or other changes.
Human and preclinical research helps test whether an idea is biologically plausible, whether it appears in people and how confidently the result can be separated from chance, bias or other parts of recovery.
A randomized chronic-fatigue trial found little difference across most clinical measures, with some secondary signals.
NADH carries electrons into cellular energy pathways, giving the idea a clear biological basis.
Biologically plausible but not a dependable broad anti-fatigue effect.
Some secondary exercise measures changed in small studies, but broad functional improvement was not established.
Cellular redox and ATP production support the hypothesis without proving a performance outcome.
An uncertain human outcome that needs better, larger trials.
A randomized combination study reported some benefits, but it cannot separate the contribution of NADH from CoQ10.
Both sit near mitochondrial energy pathways, offering a combination rationale.
Combination evidence cannot be treated as proof for NADH alone.
Community reports can surface patterns worth exploring. Controlled human research is what tests whether those patterns are reliable, clinically meaningful and attributable toNADH, while the available studies show how far that question has already been answered.
Compare published study protocols with the patterns people discuss in the community. The two are intentionally kept separate so an anecdotal routine is never mistaken for clinical guidance.
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
Human NADH studies are indication-specific and often involve chronic-fatigue populations or combination products, so they do not establish a general NADH regimen.
Adults with chronic fatigue syndrome
Published study structure, shown as data — not a personal dosing schedule.
Disease-specific research protocol; not a general wellness recommendation.
5–10 mg in the morning is a common lower supplement starting range. Products vary in formulation and absorption.
10–20 mg daily for four-to-eight weeks is often discussed when fatigue is the main goal; a small trial used 20 mg daily for two months.
There is no established long-term maintenance dose or cycling schedule for general energy, cognition or fatigue.
The summary above reflects the human or preclinical evidence currently represented on this profile.
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Persistent fatigue can reflect anaemia, sleep problems, thyroid disease, infection, medication effects or other conditions and deserves assessment rather than supplement escalation alone.
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
Human trials are small and indication-specific. They do not establish NADH as a general treatment for low energy, cognition or healthy ageing.
Randomized fatigue trial · PubMed ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.